FASN-IN-3 is a fatty acid synthase ( FASN ) inhibitor extracted from patent US20170119786A1, compound 242A In Vitro Human PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid (LTA), a Toll 2 receptor agonist. Stimulation with either LPS or LTA plus DMSO, the solvent for FASN-IN-3 (Compound 242A), results in secretion of IL-1 beta. FASN inhibitor 1 treatment of PBMC, which is a mixed population of mononuclear cells including both lymphocytes and monocytes, reduces the level of IL-1 beta resulting from either LPS or LTA stimulation. For monocytes, FASN-IN-3 treatment reduces the level of IL-1 beta resulting from LTA stimulation whereas there is only a slight reduction after LPS stimulation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:FASN
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
FASN-IN-3
CAS number：2097262-60-5 molecular formula：C24H24N4O
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2097262-60-5 | molecular formula | C24H24N4O |
| molecular weight | 384.5 g/mol | Exact mass | ≥98% |
| PSA | 72.800 Ų | logp | 4.100 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
